A Phase 2 interventional study of Blinatumomab in Diffuse Large B-cell Lymphoma, sponsored by Amgen Research (Munich) GmbH. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-06.
Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany — 15 open to participants now, 28 under way, 7 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Germany.
Among the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, this one is the 92nd largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2012, is one of 30 in phase 2, and was the 40th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →15 of the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Australia and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, France and 5 more countries
Ages 18+
AvenCell Therapeutics, Inc. · Sites in Germany, United States
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 47 · Phase 3 32 · Phase 4 1
First in 1994; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 156 across the 100 interventional studies, 595 across the 7 observational. Of the 78 that completed or were terminated, 39 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Amgen Research (Munich) GmbH, one of the names counted as Amgen. Under that name alone:
Amgen Research (Munich) GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
Amgen has 9 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
8 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT02227251Karyopharm Therapeutics IncSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 2026-12 |
| NCT03676504University Hospital HeidelbergTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | 2026-12-31 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
DLBCL is an aggressive malignant disease which evolves from B-cells and affects mainly the lymphatic tissue. Due to its aggressive nature the disease is characterized by a fast course which is lethal without therapy. Potentially curative therapy options are available even at advanced stages. Standard-first line leads to a high initial response rate (85-90%) and an approximate cure rate of 50% of patients. Patients refractory to or with early relapse after this treatment (10-15%) have a very poor prognosis.
Blinatumomab is a bispecific single-chain antibody derivative against CD19 and CD3, designed to link B-cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against CD19 expressing cells.
This study consisted of a screening period, treatment period, and a follow-up efficacy and survival period. The core study comprises the treatment period to the 30 days after the last infusion. The first cycle consisted of a continuous intravenous (CIV) infusion over 8 weeks. Participants who achieved a Complete Response (CR) or Partial Response (PR) or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval. After the last treatment cycle, efficacy and survival follow-up visits occurred for up to 24 months from treatment start. Participants who relapsed during the follow-up period may have received an additional 8 weeks of treatment.
Two dose regimens were assessed in this study. Stage 1 comprised 2 dose cohorts. In Cohort 1, the first 6 participants were to receive blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. In Cohort 2, the next 6 participants enrolled were to receive a constant dose of 112 µg/day blinatumomab. Before the initiation of stage 2, a pre-planned data monitoring committee (DMC) meeting was held to assess the safety profile of Cohort 1 and Cohort 2. The dosing regimen with the more favorable benefit-risk profile was to be selected for Cohort 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
Drug: Blinatumomab
Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
Also known as: AMG103, MT103, BLINCYTO®
Overall Objective Response Rate During Treatment Cycle 1
Overall response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all evidence of disease and partial response is defined as regression of measureable disease and no new sites.
Time frame: During the first 8 weeks
Percentage of Participants With a Best Overall Response of Complete Response
Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Complete response is defined as the disappearance of all evidence of disease.
Time frame: During the first 8 weeks
Percentage of Participants With a Best Overall Response of Partial Response
Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Partial response is defined as regression (\<50% decrease in size of masses) of measureable disease and no new sites.
Time frame: During the first 8 weeks
Duration of Objective Response
The time from documentation of the first assessment of either partial or complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Duration of Complete Response
The time from documentation of the first assessment of complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Duration of Partial Response
The time from documentation of the first assessment of partial response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Progression-free Survival (PFS)
The time from the date of first blinatumomab infusion until the date of diagnosis of progression of lymphoma, the start date of new anti-tumor treatment (excluding any stem cell transplantation) or date of death, whichever is the earliest. Patients alive who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were censored at last date of tumor assessment.
Time frame: From first infusion of blinatumomab until the end of study; median time on follow-up for PFS was 27.0 months.
Overall Survival (OS)
The time from the date of first blinatumomab infusion until death as a result of any cause. Patients still alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. For patients who withdrew their informed consent, only information until the date of withdrawal was analyzed.
Time frame: From the first infusion of blinatumomab until the end of study; median time on follow-up for overall survival was 26.6 months.
Number of Participants With Adverse Events
Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. An adverse event or suspected adverse drug reaction was considered "serious" if it resulted in one of the following outcomes: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions; * Was a congenital anomaly or birth defect; * Was a medically important condition. The Investigator used medical judgment to determine whether there was a causal relationship (ie, related \[reasonably possible\] or unrelated \[not reasonably possible\]) between an adverse event and blinatumomab.
Time frame: From the first dose of blinatumomab until up to 30 days after the last dose or until the data cut-off date of 10 July 2014, whichever occurred first; the overall median duration of treatment exposure was 46.8 days.
Blinatumomab Steady State Serum Concentration
Blinatumomab serum levels were analyzed using a validated cluster of differentiation (CD)69 activation bioassay with a lower limit of quantification (LLOQ) of 50 pg/mL. Steady-state concentration (Css) was based on actual dose received, rather than based on cohort or time or day.
Time frame: Cycle 1: predose; Day 3 and Day 8 (Css for 9 ug/day); Day 15 (Css for 28 ug/day); and Day 29, Day 43 and Day 57 (Css for 112 ug/day)
Leukocyte Counts
Leukocyte (white blood cells) counts were analyzed by differential blood count analysis.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Lymphocyte Counts
Lymphocyte counts were analyzed by differential blood count analysis.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Monocyte Counts
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Granulocyte Count
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD19+ B-Cell Count
CD19+ B-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD19+ B-Cells as a Percentage of All Lymphocytes
CD19+ B-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD3+ T-Cell Count
CD3+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD3+ T-Cells as a Percentage of All Lymphocytes
CD3+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ T-Cell Count
CD4+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ T-Cells as a Percentage of All Lymphocytes
CD4+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ T-Cell Count
CD8+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ T-Cells as a Percentage of All Lymphocytes
CD8+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD19+ B-Cell to CD3+ T-Cell Ratio
CD19+ B-cells and CD3+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ T-Cell to CD8+ T-Cell Ratio
CD4+ T-cells and CD8+ T-cell counts were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ Naive T Cell Count
CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells
CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ Central Memory T-Cell (TCM) Count
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ Effector Memory T-Cell (TEM) Count
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ Naive T-Cell Count
CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells
CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ TCM Cell Counts
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ Effector Memory T-Cell (TEM) Count
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count
Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells
Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.
Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Adults with a diagnosis of diffuse large B-cell lymphoma (DLBCL) which was refractory to first or subsequent treatment or who had a first or later relapse and were not eligible for autologous hematopoietic stem cell transplant (HSCT), or relapsed after autologous HSCT were eligible to enrol. The primary analysis cut-off date was 10 July 2014.
| Milestone | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d |
|---|---|---|---|
| Started | 9 | 2 | 14 |
| Efficacy set | 7 | 1 | 13 |
| Completed | 3 | 1 | 2 |
| Not completed | 6 | 1 | 12 |
| Withdrew: Death | 6 | 1 | 12 |
Overall response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all evidence of disease and partial response is defined as regression of measureable disease and no new sites.
| percentage of participants | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Overall Objective Response Rate During Treatment Cycle 1 | 57.1 (18.4 to 90.1) | 100.0 (2.5 to 100.0) | 30.8 (9.1 to 61.4) |
Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Complete response is defined as the disappearance of all evidence of disease.
| percentage of participants | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 15.4 (1.9 to 45.4) |
Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Partial response is defined as regression (\<50% decrease in size of masses) of measureable disease and no new sites.
| percentage of participants | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of Partial Response | 28.6 (3.7 to 71.0) | 100.0 (2.5 to 100.0) | 15.4 (1.9 to 45.4) |
The time from documentation of the first assessment of either partial or complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
| months | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Duration of Objective Response | 8.7 (0.9 to NA) | NA (NA to NA) | 4.0 (1.9 to NA) |
The time from documentation of the first assessment of complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
| months | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Duration of Complete Response | NA (11.6 to NA) | — | NA (5.9 to NA) |
The time from documentation of the first assessment of partial response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.
| months | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Duration of Partial Response | 3.3 (0.9 to 5.8) | NA (NA to NA) | 2.0 (1.9 to 2.1) |
The time from the date of first blinatumomab infusion until the date of diagnosis of progression of lymphoma, the start date of new anti-tumor treatment (excluding any stem cell transplantation) or date of death, whichever is the earliest. Patients alive who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were censored at last date of tumor assessment.
| months | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Progression-free Survival (PFS) | 3.7 (0.7 to 14.1) | NA (NA to NA) | 1.6 (0.6 to 4.6) |
The time from the date of first blinatumomab infusion until death as a result of any cause. Patients still alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. For patients who withdrew their informed consent, only information until the date of withdrawal was analyzed.
| months | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Overall Survival (OS) | 20.1 (2.3 to NA) | NA (NA to NA) | 3.6 (1.5 to 14.8) |
Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. An adverse event or suspected adverse drug reaction was considered "serious" if it resulted in one of the following outcomes: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions; * Was a congenital anomaly or birth defect; * Was a medically important condition. The Investigator used medical judgment to determine whether there was a causal relationship (ie, related \[reasonably possible\] or unrelated \[not reasonably possible\]) between an adverse event and blinatumomab.
| participants | Cohort 1: Blinatumomab 9/28/112 μg/d | Cohort 2: Blinatumomab 112 μg/d | Cohort 3: Blinatumomab 9/28/112 μg/d |
|---|---|---|---|
| Any adverse event (AE) | 9 | 2 | 14 |
| AE of Grade ≥ 3 | 9 | 2 | 13 |
| AE of Grade ≥ 4 | 0 | 2 | 6 |
| Serious adverse event (SAE) | 9 | 2 | 12 |
| Fatal adverse events | 0 | 0 | 2 |
| Led to discontinuation of study drug | 3 | 1 | 2 |
| Led to interruption of study drug | 4 | 1 | 6 |
| Related adverse events | 9 | 2 | 11 |
| Related AE Grade ≥ 3 | 5 | 2 | 5 |
| Related AE Grade ≥ 4 | 0 | 1 | 2 |
| Serious related adverse events | 5 | 2 | 3 |
| Related AE led to discontinuation of study drug | 2 | 1 | 2 |
| Related AE led to interruption of study drug | 3 | 1 | 3 |
Blinatumomab serum levels were analyzed using a validated cluster of differentiation (CD)69 activation bioassay with a lower limit of quantification (LLOQ) of 50 pg/mL. Steady-state concentration (Css) was based on actual dose received, rather than based on cohort or time or day.
| pg/mL | Blinatumomab 9 μg/d | Blinatumomab 28 μg/d | Blinatumomab 112 μg/d |
|---|---|---|---|
| Blinatumomab Steady State Serum Concentration | 277 ± 210 | 565 ± 208 | 2800 ± 1150 |
Leukocyte (white blood cells) counts were analyzed by differential blood count analysis.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 6.376 ± 3.284 |
| Day 1 Prior (N = 24) | 5.729 ± 2.891 |
| Day 8 (N = 21) | 6.819 ± 3.201 |
| Day 15 (N = 16) | 6.400 ± 2.486 |
| Day 29 (N = 11) | 3.764 ± 2.160 |
| Day 43 (N = 8) | 4.950 ± 3.819 |
| End of Infusion (N = 9) | 4.611 ± 2.114 |
| End of Core Study (N = 6) | 6.850 ± 2.818 |
| 3-Month Follow-up (N = 5) | 4.820 ± 1.616 |
| 6-Month Follow-up (N = 6) | 5.183 ± 1.380 |
| 9-Month Follow-up (N = 4) | 4.425 ± 0.854 |
| 12-Month Follow-up (N = 4) | 5.700 ± 1.424 |
| 15-Month Follow-up (N = 3) | 4.767 ± 0.874 |
| 18-Month Follow-up (N = 3) | 6.467 ± 1.779 |
| 21-Month Follow-up (N = 21) | 5.450 ± 0.495 |
| 24-Month Follow-up (N = 3) | 4.533 ± 1.069 |
Lymphocyte counts were analyzed by differential blood count analysis.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.779 ± 0.425 |
| Day 1 Prior (N = 24) | 0.491 ± 0.259 |
| Day 8 (N = 21) | 0.382 ± 0.215 |
| Day 15 (N = 16) | 0.277 ± 0.165 |
| Day 29 (N = 11) | 0.472 ± 0.273 |
| Day 43 (N = 8) | 0.847 ± 0.511 |
| End of Infusion (N = 9) | 0.767 ± 0.505 |
| End of Core Study (N = 6) | 1.060 ± 0.489 |
| 3-Month Follow-up (N = 5) | 1.053 ± 0.421 |
| 6-Month Follow-up (N = 6) | 1.120 ± 0.621 |
| 9-Month Follow-up (N = 4) | 1.048 ± 0.381 |
| 12-Month Follow-up (N = 4) | 1.120 ± 0.449 |
| 15-Month Follow-up (N = 3) | 0.998 ± 0.527 |
| 18-Month Follow-up (N = 3) | 0.565 ± 0.180 |
| 21-Month Follow-up (N = 21) | 1.205 ± 0.839 |
| 24-Month Follow-up (N = 3) | 0.737 ± 0.478 |
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.638 ± 0.415 |
| Day 1 Prior (N = 24) | 0.300 ± 0.565 |
| Day 8 (N = 21) | 0.202 ± 0.386 |
| Day 15 (N = 16) | 0.188 ± 0.317 |
| Day 29 (N = 11) | 0.318 ± 0.185 |
| Day 43 (N = 8) | 0.646 ± 0.375 |
| End of Infusion (N = 9) | 0.473 ± 0.241 |
| End of Core Study (N = 6) | 0.711 ± 0.569 |
| 3-Month Follow-up (N = 5) | 0.585 ± 0.280 |
| 6-Month Follow-up (N = 6) | 0.487 ± 0.239 |
| 9-Month Follow-up (N = 4) | 0.452 ± 0.112 |
| 12-Month Follow-up (N = 4) | 0.469 ± 0.061 |
| 15-Month Follow-up (N = 3) | 0.511 ± 0.053 |
| 18-Month Follow-up (N = 3) | 0.290 ± 0.123 |
| 21-Month Follow-up (N = 21) | 0.516 ± 0.008 |
| 24-Month Follow-up (N = 3) | 0.234 ± 0.176 |
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 4.968 ± 3.187 |
| Day 1 Prior (N = 24) | 4.910 ± 2.425 |
| Day 8 (N = 21) | 6.235 ± 2.881 |
| Day 15 (N = 16) | 5.935 ± 2.387 |
| Day 29 (N = 11) | 2.974 ± 2.019 |
| Day 43 (N = 8) | 3.457 ± 3.395 |
| End of Infusion (N = 9) | 3.353 ± 2.134 |
| End of Core Study (N = 6) | 5.080 ± 3.012 |
| 3-Month Follow-up (N = 5) | 3.182 ± 1.117 |
| 6-Month Follow-up (N = 6) | 3.594 ± 0.950 |
| 9-Month Follow-up (N = 4) | 2.925 ± 0.675 |
| 12-Month Follow-up (N = 4) | 4.111 ± 1.382 |
| 15-Month Follow-up (N = 3) | 3.258 ± 0.745 |
| 18-Month Follow-up (N = 3) | 5.612 ± 1.713 |
| 21-Month Follow-up (N = 21) | 3.729 ± 0.352 |
| 24-Month Follow-up (N = 3) | 3.563 ± 0.711 |
CD19+ B-cell counts were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.026 ± 0.072 |
| Day 1 Prior (N = 24) | 0.029 ± 0.085 |
| Day 8 (N = 21) | 0.001 ± 0.002 |
| Day 15 (N = 16) | 0.000 ± 0.001 |
| Day 29 (N = 11) | 0.000 ± 0.000 |
| Day 43 (N = 8) | 0.000 ± 0.001 |
| End of Infusion (N = 9) | 0.001 ± 0.001 |
| End of Core Study (N = 6) | 0.001 ± 0.002 |
| 3-Month Follow-up (N = 5) | 0.025 ± 0.026 |
| 6-Month Follow-up (N = 6) | 0.029 ± 0.043 |
| 9-Month Follow-up (N = 4) | 0.054 ± 0.066 |
| 12-Month Follow-up (N = 4) | 0.082 ± 0.113 |
| 15-Month Follow-up (N = 3) | 0.094 ± 0.118 |
| 18-Month Follow-up (N = 3) | 0.071 ± 0.075 |
| 21-Month Follow-up (N = 21) | 0.131 ± 0.170 |
| 24-Month Follow-up (N = 3) | 0.108 ± 0.120 |
CD19+ B-cell counts were analyzed by flow cytometry.
| percentage of lymphocytes | Blinatumomab |
|---|---|
| Screening (N = 25) | 2 ± 7 |
| Day 1 Prior (N = 24) | 4 ± 9 |
| Day 8 (N = 21) | 0 ± 0 |
| Day 15 (N = 16) | 0 ± 0 |
| Day 29 (N = 11) | 0 ± 0 |
| Day 43 (N = 8) | 0 ± 0 |
| End of Infusion (N = 9) | 0 ± 0 |
| End of Core Study (N = 6) | 0 ± 0 |
| 3-Month Follow-up (N = 5) | 2 ± 2 |
| 6-Month Follow-up (N = 6) | 2 ± 3 |
| 9-Month Follow-up (N = 4) | 5 ± 5 |
| 12-Month Follow-up (N = 4) | 7 ± 9 |
| 15-Month Follow-up (N = 3) | 7 ± 7 |
| 18-Month Follow-up (N = 3) | 11 ± 9 |
| 21-Month Follow-up (N = 21) | 8 ± 8 |
| 24-Month Follow-up (N = 3) | 12 ± 7 |
CD3+ T-cell counts were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.578 ± 0.355 |
| Day 1 Prior (N = 24) | 0.349 ± 0.233 |
| Day 8 (N = 21) | 0.282 ± 0.194 |
| Day 15 (N = 16) | 0.199 ± 0.159 |
| Day 29 (N = 11) | 0.348 ± 0.231 |
| Day 43 (N = 8) | 0.613 ± 0.426 |
| End of Infusion (N = 9) | 0.543 ± 0.421 |
| End of Core Study (N = 6) | 0.825 ± 0.431 |
| 3-Month Follow-up (N = 5) | 0.773 ± 0.443 |
| 6-Month Follow-up (N = 6) | 0.782 ± 0.345 |
| 9-Month Follow-up (N = 4) | 0.671 ± 0.184 |
| 12-Month Follow-up (N = 4) | 0.703 ± 0.203 |
| 15-Month Follow-up (N = 3) | 0.594 ± 0.227 |
| 18-Month Follow-up (N = 3) | 0.298 ± 0.049 |
| 21-Month Follow-up (N = 21) | 0.623 ± 0.266 |
| 24-Month Follow-up (N = 3) | 0.456 ± 0.257 |
CD3+ T-cell counts were analyzed by flow cytometry.
| percentage of lymphocytes | Blinatumomab |
|---|---|
| Screening (N = 25) | 72 ± 14 |
| Day 1 Prior (N = 24) | 68 ± 18 |
| Day 8 (N = 21) | 70 ± 19 |
| Day 15 (N = 16) | 67 ± 19 |
| Day 29 (N = 11) | 73 ± 15 |
| Day 43 (N = 8) | 71 ± 13 |
| End of Infusion (N = 9) | 66 ± 14 |
| End of Core Study (N = 6) | 76 ± 16 |
| 3-Month Follow-up (N = 5) | 73 ± 11 |
| 6-Month Follow-up (N = 6) | 66 ± 21 |
| 9-Month Follow-up (N = 4) | 66 ± 6 |
| 12-Month Follow-up (N = 4) | 65 ± 9 |
| 15-Month Follow-up (N = 3) | 61 ± 7 |
| 18-Month Follow-up (N = 3) | 57 ± 20 |
| 21-Month Follow-up (N = 21) | 58 ± 16 |
| 24-Month Follow-up (N = 3) | 63 ± 8 |
CD4+ T-cell counts were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.254 ± 0.160 |
| Day 1 Prior (N = 24) | 0.152 ± 0.128 |
| Day 8 (N = 21) | 0.131 ± 0.128 |
| Day 15 (N = 16) | 0.085 ± 0.084 |
| Day 29 (N = 11) | 0.170 ± 0.172 |
| Day 43 (N = 8) | 0.261 ± 0.219 |
| End of Infusion (N = 9) | 0.241 ± 0.254 |
| End of Core Study (N = 6) | 0.375 ± 0.251 |
| 3-Month Follow-up (N = 5) | 0.371 ± 0.216 |
| 6-Month Follow-up (N = 6) | 0.371 ± 0.237 |
| 9-Month Follow-up (N = 4) | 0.309 ± 0.184 |
| 12-Month Follow-up (N = 4) | 0.399 ± 0.193 |
| 15-Month Follow-up (N = 3) | 0.326 ± 0.220 |
| 18-Month Follow-up (N = 3) | 0.178 ± 0.042 |
| 21-Month Follow-up (N = 21) | 0.373 ± 0.279 |
| 24-Month Follow-up (N = 3) | 0.258 ± 0.248 |
CD4+ T-cell counts were analyzed by flow cytometry.
| percentage of lymphocytes | Blinatumomab |
|---|---|
| Screening (N = 25) | 33 ± 11 |
| Day 1 Prior (N = 24) | 28 ± 14 |
| Day 8 (N = 21) | 32 ± 17 |
| Day 15 (N = 16) | 29 ± 13 |
| Day 29 (N = 11) | 34 ± 18 |
| Day 43 (N = 8) | 30 ± 12 |
| End of Infusion (N = 9) | 28 ± 13 |
| End of Core Study (N = 6) | 32 ± 15 |
| 3-Month Follow-up (N = 5) | 33 ± 9 |
| 6-Month Follow-up (N = 6) | 30 ± 10 |
| 9-Month Follow-up (N = 4) | 31 ± 13 |
| 12-Month Follow-up (N = 4) | 35 ± 7 |
| 15-Month Follow-up (N = 3) | 31 ± 7 |
| 18-Month Follow-up (N = 3) | 32 ± 6 |
| 21-Month Follow-up (N = 21) | 29 ± 4 |
| 24-Month Follow-up (N = 3) | 34 ± 8 |
CD8+ T-cell counts were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.298 ± 0.256 |
| Day 1 Prior (N = 24) | 0.186 ± 0.136 |
| Day 8 (N = 21) | 0.134 ± 0.099 |
| Day 15 (N = 16) | 0.102 ± 0.095 |
| Day 29 (N = 11) | 0.140 ± 0.076 |
| Day 43 (N = 8) | 0.299 ± 0.237 |
| End of Infusion (N = 9) | 0.284 ± 0.195 |
| End of Core Study (N = 6) | 0.438 ± 0.284 |
| 3-Month Follow-up (N = 5) | 0.381 ± 0.254 |
| 6-Month Follow-up (N = 6) | 0.403 ± 0.304 |
| 9-Month Follow-up (N = 4) | 0.225 ± 0.039 |
| 12-Month Follow-up (N = 4) | 0.310 ± 0.200 |
| 15-Month Follow-up (N = 3) | 0.214 ± 0.023 |
| 18-Month Follow-up (N = 3) | 0.105 ± 0.057 |
| 21-Month Follow-up (N = 21) | 0.185 ± 0.026 |
| 24-Month Follow-up (N = 3) | 0.187 ± 0.068 |
CD8+ T-cell counts were analyzed by flow cytometry.
| percentage of lymphocytes | Blinatumomab |
|---|---|
| Screening (N = 25) | 37 ± 18 |
| Day 1 Prior (N = 24) | 37 ± 19 |
| Day 8 (N = 21) | 35 ± 19 |
| Day 15 (N = 16) | 35 ± 17 |
| Day 29 (N = 11) | 33 ± 17 |
| Day 43 (N = 8) | 37 ± 15 |
| End of Infusion (N = 9) | 36 ± 16 |
| End of Core Study (N = 6) | 43 ± 23 |
| 3-Month Follow-up (N = 5) | 36 ± 19 |
| 6-Month Follow-up (N = 6) | 34 ± 16 |
| 9-Month Follow-up (N = 4) | 25 ± 11 |
| 12-Month Follow-up (N = 4) | 28 ± 13 |
| 15-Month Follow-up (N = 3) | 24 ± 9 |
| 18-Month Follow-up (N = 3) | 21 ± 13 |
| 21-Month Follow-up (N = 21) | 20 ± 12 |
| 24-Month Follow-up (N = 3) | 27 ± 16 |
CD19+ B-cells and CD3+ T-cell counts were analyzed by flow cytometry.
| ratio | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.04 ± 0.15 |
| Day 1 Prior (N = 24) | 0.07 ± 0.24 |
| Day 8 (N = 21) | 0.00 ± 0.01 |
| Day 15 (N = 16) | 0.00 ± 0.00 |
| Day 29 (N = 11) | 0.00 ± 0.00 |
| Day 43 (N = 8) | 0.00 ± 0.00 |
| End of Infusion (N = 9) | 0.00 ± 0.01 |
| End of Core Study (N = 6) | 0.00 ± 0.00 |
| 3-Month Follow-up (N = 5) | 0.03 ± 0.03 |
| 6-Month Follow-up (N = 6) | 0.04 ± 0.05 |
| 9-Month Follow-up (N = 4) | 0.08 ± 0.08 |
| 12-Month Follow-up (N = 4) | 0.12 ± 0.15 |
| 15-Month Follow-up (N = 3) | 0.13 ± 0.13 |
| 18-Month Follow-up (N = 3) | 0.25 ± 0.30 |
| 21-Month Follow-up (N = 21) | 0.17 ± 0.20 |
| 24-Month Follow-up (N = 3) | 0.19 ± 0.13 |
CD4+ T-cells and CD8+ T-cell counts were analyzed by flow cytometry.
| ratio | Blinatumomab |
|---|---|
| Screening (N = 25) | 1.32 ± 1.19 |
| Day 1 Prior (N = 24) | 1.16 ± 1.45 |
| Day 8 (N = 21) | 1.20 ± 0.96 |
| Day 15 (N = 16) | 1.03 ± 0.71 |
| Day 29 (N = 11) | 1.43 ± 1.08 |
| Day 43 (N = 8) | 0.96 ± 0.53 |
| End of Infusion (N = 9) | 1.09 ± 1.00 |
| End of Core Study (N = 6) | 1.03 ± 0.80 |
| 3-Month Follow-up (N = 5) | 1.18 ± 0.79 |
| 6-Month Follow-up (N = 6) | 1.10 ± 0.70 |
| 9-Month Follow-up (N = 4) | 1.53 ± 1.25 |
| 12-Month Follow-up (N = 4) | 1.70 ± 1.47 |
| 15-Month Follow-up (N = 3) | 1.47 ± 0.81 |
| 18-Month Follow-up (N = 3) | 2.23 ± 1.70 |
| 21-Month Follow-up (N = 21) | 1.85 ± 1.34 |
| 24-Month Follow-up (N = 3) | 1.73 ± 1.21 |
CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.028 ± 0.056 |
| Day 1 Prior (N = 24) | 0.013 ± 0.022 |
| Day 8 (N = 21) | 0.014 ± 0.033 |
| Day 15 (N = 16) | 0.012 ± 0.024 |
| Day 29 (N = 11) | 0.032 ± 0.071 |
| Day 43 (N = 8) | 0.036 ± 0.060 |
| End of Infusion (N = 9) | 0.037 ± 0.088 |
| End of Core Study (N = 6) | 0.050 ± 0.083 |
| 3-Month Follow-up (N = 5) | 0.015 ± 0.019 |
| 6-Month Follow-up (N = 6) | 0.023 ± 0.044 |
| 9-Month Follow-up (N = 4) | 0.053 ± 0.090 |
| 12-Month Follow-up (N = 4) | 0.053 ± 0.084 |
| 15-Month Follow-up (N = 3) | 0.044 ± 0.059 |
| 18-Month Follow-up (N = 3) | 0.035 ± 0.041 |
| 21-Month Follow-up (N = 21) | 0.098 ± 0.103 |
| 24-Month Follow-up (N = 3) | 0.016 ± 0.013 |
CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
| percentage of CD4+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 8 ± 9 |
| Day 1 Prior (N = 24) | 7 ± 7 |
| Day 8 (N = 21) | 7 ± 7 |
| Day 15 (N = 16) | 10 ± 9 |
| Day 29 (N = 11) | 9 ± 11 |
| Day 43 (N = 8) | 10 ± 10 |
| End of Infusion (N = 9) | 8 ± 9 |
| End of Core Study (N = 6) | 9 ± 13 |
| 3-Month Follow-up (N = 5) | 4 ± 3 |
| 6-Month Follow-up (N = 6) | 4 ± 7 |
| 9-Month Follow-up (N = 4) | 11 ± 15 |
| 12-Month Follow-up (N = 4) | 12 ± 14 |
| 15-Month Follow-up (N = 3) | 10 ± 9 |
| 18-Month Follow-up (N = 3) | 19 ± 19 |
| 21-Month Follow-up (N = 21) | 23 ± 9 |
| 24-Month Follow-up (N = 3) | 8 ± 10 |
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.048 ± 0.053 |
| Day 1 Prior (N = 24) | 0.029 ± 0.034 |
| Day 8 (N = 21) | 0.027 ± 0.042 |
| Day 15 (N = 16) | 0.014 ± 0.025 |
| Day 29 (N = 11) | 0.032 ± 0.065 |
| Day 43 (N = 8) | 0.032 ± 0.035 |
| End of Infusion (N = 9) | 0.049 ± 0.103 |
| End of Core Study (N = 6) | 0.062 ± 0.075 |
| 3-Month Follow-up (N = 5) | 0.019 ± 0.009 |
| 6-Month Follow-up (N = 6) | 0.027 ± 0.020 |
| 9-Month Follow-up (N = 4) | 0.043 ± 0.056 |
| 12-Month Follow-up (N = 4) | 0.065 ± 0.073 |
| 15-Month Follow-up (N = 3) | 0.039 ± 0.020 |
| 18-Month Follow-up (N = 3) | 0.033 ± 0.031 |
| 21-Month Follow-up (N = 21) | 0.056 ± 0.054 |
| 24-Month Follow-up (N = 3) | 0.021 ± 0.010 |
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
| percentage of CD4+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 18 ± 12 |
| Day 1 Prior (N = 24) | 20 ± 15 |
| Day 8 (N = 21) | 19 ± 15 |
| Day 15 (N = 16) | 14 ± 12 |
| Day 29 (N = 11) | 13 ± 10 |
| Day 43 (N = 8) | 13 ± 9 |
| End of Infusion (N = 9) | 15 ± 11 |
| End of Core Study (N = 6) | 14 ± 11 |
| 3-Month Follow-up (N = 5) | 6 ± 3 |
| 6-Month Follow-up (N = 6) | 9 ± 4 |
| 9-Month Follow-up (N = 4) | 11 ± 9 |
| 12-Month Follow-up (N = 4) | 18 ± 16 |
| 15-Month Follow-up (N = 3) | 13 ± 6 |
| 18-Month Follow-up (N = 3) | 18 ± 14 |
| 21-Month Follow-up (N = 21) | 14 ± 4 |
| 24-Month Follow-up (N = 3) | 12 ± 11 |
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.161 ± 0.089 |
| Day 1 Prior (N = 24) | 0.099 ± 0.096 |
| Day 8 (N = 21) | 0.083 ± 0.076 |
| Day 15 (N = 16) | 0.051 ± 0.044 |
| Day 29 (N = 11) | 0.097 ± 0.059 |
| Day 43 (N = 8) | 0.169 ± 0.117 |
| End of Infusion (N = 9) | 0.140 ± 0.091 |
| End of Core Study (N = 6) | 0.220 ± 0.142 |
| 3-Month Follow-up (N = 5) | 0.279 ± 0.153 |
| 6-Month Follow-up (N = 6) | 0.267 ± 0.158 |
| 9-Month Follow-up (N = 4) | 0.191 ± 0.037 |
| 12-Month Follow-up (N = 4) | 0.226 ± 0.100 |
| 15-Month Follow-up (N = 3) | 0.199 ± 0.087 |
| 18-Month Follow-up (N = 3) | 0.106 ± 0.066 |
| 21-Month Follow-up (N = 21) | 0.181 ± 0.107 |
| 24-Month Follow-up (N = 3) | 0.175 ± 0.133 |
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
| percentage of CD4+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 41 ± 19 |
| Day 1 Prior (N = 24) | 39 ± 19 |
| Day 8 (N = 21) | 36 ± 19 |
| Day 15 (N = 16) | 46 ± 17 |
| Day 29 (N = 11) | 34 ± 20 |
| Day 43 (N = 8) | 39 ± 26 |
| End of Infusion (N = 9) | 41 ± 24 |
| End of Core Study (N = 6) | 41 ± 24 |
| 3-Month Follow-up (N = 5) | 46 ± 26 |
| 6-Month Follow-up (N = 6) | 41 ± 21 |
| 9-Month Follow-up (N = 4) | 42 ± 18 |
| 12-Month Follow-up (N = 4) | 40 ± 15 |
| 15-Month Follow-up (N = 3) | 46 ± 17 |
| 18-Month Follow-up (N = 3) | 43 ± 12 |
| 21-Month Follow-up (N = 21) | 45 ± 3 |
| 24-Month Follow-up (N = 3) | 51 ± 22 |
CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.029 ± 0.043 |
| Day 1 Prior (N = 24) | 0.024 ± 0.050 |
| Day 8 (N = 21) | 0.010 ± 0.012 |
| Day 15 (N = 16) | 0.006 ± 0.005 |
| Day 29 (N = 11) | 0.012 ± 0.014 |
| Day 43 (N = 8) | 0.019 ± 0.036 |
| End of Infusion (N = 9) | 0.011 ± 0.015 |
| End of Core Study (N = 6) | 0.023 ± 0.018 |
| 3-Month Follow-up (N = 5) | 0.011 ± 0.007 |
| 6-Month Follow-up (N = 6) | 0.020 ± 0.022 |
| 9-Month Follow-up (N = 4) | 0.011 ± 0.012 |
| 12-Month Follow-up (N = 4) | 0.011 ± 0.009 |
| 15-Month Follow-up (N = 3) | 0.014 ± 0.011 |
| 18-Month Follow-up (N = 3) | 0.007 ± 0.008 |
| 21-Month Follow-up (N = 21) | 0.015 ± 0.006 |
| 24-Month Follow-up (N = 3) | 0.010 ± 0.009 |
CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.
| percentage of CD8+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 10 ± 10 |
| Day 1 Prior (N = 24) | 12 ± 13 |
| Day 8 (N = 21) | 9 ± 8 |
| Day 15 (N = 16) | 8 ± 7 |
| Day 29 (N = 11) | 8 ± 7 |
| Day 43 (N = 8) | 6 ± 7 |
| End of Infusion (N = 9) | 3 ± 3 |
| End of Core Study (N = 6) | 6 ± 6 |
| 3-Month Follow-up (N = 5) | 4 ± 4 |
| 6-Month Follow-up (N = 6) | 5 ± 5 |
| 9-Month Follow-up (N = 4) | 6 ± 7 |
| 12-Month Follow-up (N = 4) | 6 ± 6 |
| 15-Month Follow-up (N = 3) | 6 ± 5 |
| 18-Month Follow-up (N = 3) | 10 ± 8 |
| 21-Month Follow-up (N = 21) | 8 ± 4 |
| 24-Month Follow-up (N = 3) | 10 ± 12 |
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
| 100 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.020 ± 0.027 |
| Day 1 Prior (N = 24) | 0.014 ± 0.021 |
| Day 8 (N = 21) | 0.010 ± 0.013 |
| Day 15 (N = 16) | 0.004 ± 0.005 |
| Day 29 (N = 11) | 0.007 ± 0.007 |
| Day 43 (N = 8) | 0.012 ± 0.015 |
| End of Infusion (N = 9) | 0.009 ± 0.009 |
| End of Core Study (N = 6) | 0.016 ± 0.023 |
| 3-Month Follow-up (N = 5) | 0.008 ± 0.003 |
| 6-Month Follow-up (N = 6) | 0.016 ± 0.014 |
| 9-Month Follow-up (N = 4) | 0.006 ± 0.004 |
| 12-Month Follow-up (N = 4) | 0.010 ± 0.010 |
| 15-Month Follow-up (N = 3) | 0.004 ± 0.002 |
| 18-Month Follow-up (N = 3) | 0.002 ± 0.001 |
| 21-Month Follow-up (N = 21) | 0.002 ± 0.001 |
| 24-Month Follow-up (N = 3) | 0.006 ± 0.004 |
Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.
| percentage of CD8+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 7 ± 7 |
| Day 1 Prior (N = 24) | 8 ± 11 |
| Day 8 (N = 21) | 10 ± 13 |
| Day 15 (N = 16) | 4 ± 5 |
| Day 29 (N = 11) | 7 ± 10 |
| Day 43 (N = 8) | 9 ± 18 |
| End of Infusion (N = 9) | 5 ± 6 |
| End of Core Study (N = 6) | 5 ± 8 |
| 3-Month Follow-up (N = 5) | 3 ± 2 |
| 6-Month Follow-up (N = 6) | 4 ± 3 |
| 9-Month Follow-up (N = 4) | 3 ± 2 |
| 12-Month Follow-up (N = 4) | 3 ± 3 |
| 15-Month Follow-up (N = 3) | 2 ± 1 |
| 18-Month Follow-up (N = 3) | 2 ± 1 |
| 21-Month Follow-up (N = 21) | 1 ± 0 |
| 24-Month Follow-up (N = 3) | 6 ± 8 |
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.127 ± 0.162 |
| Day 1 Prior (N = 24) | 0.075 ± 0.066 |
| Day 8 (N = 21) | 0.065 ± 0.058 |
| Day 15 (N = 16) | 0.045 ± 0.053 |
| Day 29 (N = 11) | 0.067 ± 0.039 |
| Day 43 (N = 8) | 0.135 ± 0.108 |
| End of Infusion (N = 9) | 0.128 ± 0.077 |
| End of Core Study (N = 6) | 0.180 ± 0.089 |
| 3-Month Follow-up (N = 5) | 0.146 ± 0.071 |
| 6-Month Follow-up (N = 6) | 0.179 ± 0.158 |
| 9-Month Follow-up (N = 4) | 0.116 ± 0.061 |
| 12-Month Follow-up (N = 4) | 0.174 ± 0.162 |
| 15-Month Follow-up (N = 3) | 0.095 ± 0.025 |
| 18-Month Follow-up (N = 3) | 0.049 ± 0.027 |
| 21-Month Follow-up (N = 21) | 0.085 ± 0.013 |
| 24-Month Follow-up (N = 3) | 0.054 ± 0.027 |
Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.
| percentage of CD8+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 42 ± 19 |
| Day 1 Prior (N = 24) | 42 ± 17 |
| Day 8 (N = 21) | 46 ± 18 |
| Day 15 (N = 16) | 43 ± 13 |
| Day 29 (N = 11) | 51 ± 19 |
| Day 43 (N = 8) | 46 ± 23 |
| End of Infusion (N = 9) | 51 ± 21 |
| End of Core Study (N = 6) | 49 ± 22 |
| 3-Month Follow-up (N = 5) | 47 ± 23 |
| 6-Month Follow-up (N = 6) | 50 ± 24 |
| 9-Month Follow-up (N = 4) | 50 ± 21 |
| 12-Month Follow-up (N = 4) | 51 ± 13 |
| 15-Month Follow-up (N = 3) | 46 ± 15 |
| 18-Month Follow-up (N = 3) | 46 ± 7 |
| 21-Month Follow-up (N = 21) | 46 ± 1 |
| 24-Month Follow-up (N = 3) | 33 ± 9 |
Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.
| 1000 cells/µL | Blinatumomab |
|---|---|
| Screening (N = 25) | 0.123 ± 0.099 |
| Day 1 Prior (N = 24) | 0.072 ± 0.069 |
| Day 8 (N = 21) | 0.051 ± 0.042 |
| Day 15 (N = 16) | 0.047 ± 0.048 |
| Day 29 (N = 11) | 0.058 ± 0.050 |
| Day 43 (N = 8) | 0.132 ± 0.126 |
| End of Infusion (N = 9) | 0.135 ± 0.131 |
| End of Core Study (N = 6) | 0.226 ± 0.249 |
| 3-Month Follow-up (N = 5) | 0.214 ± 0.220 |
| 6-Month Follow-up (N = 6) | 0.187 ± 0.182 |
| 9-Month Follow-up (N = 4) | 0.094 ± 0.046 |
| 12-Month Follow-up (N = 4) | 0.117 ± 0.065 |
| 15-Month Follow-up (N = 3) | 0.099 ± 0.041 |
| 18-Month Follow-up (N = 3) | 0.047 ± 0.035 |
| 21-Month Follow-up (N = 21) | 0.086 ± 0.016 |
| 24-Month Follow-up (N = 3) | 0.100 ± 0.084 |
Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.
| percentage of CD8+ T-cells | Blinatumomab |
|---|---|
| Screening (N = 25) | 41 ± 19 |
| Day 1 Prior (N = 24) | 39 ± 19 |
| Day 8 (N = 21) | 36 ± 19 |
| Day 15 (N = 16) | 46 ± 17 |
| Day 29 (N = 11) | 34 ± 20 |
| Day 43 (N = 8) | 39 ± 26 |
| End of Infusion (N = 9) | 41 ± 24 |
| End of Core Study (N = 6) | 41 ± 24 |
| 3-Month Follow-up (N = 5) | 46 ± 26 |
| 6-Month Follow-up (N = 6) | 41 ± 21 |
| 9-Month Follow-up (N = 4) | 42 ± 18 |
| 12-Month Follow-up (N = 4) | 40 ± 15 |
| 15-Month Follow-up (N = 3) | 46 ± 17 |
| 18-Month Follow-up (N = 3) | 43 ± 12 |
| 21-Month Follow-up (N = 21) | 45 ± 3 |
| 24-Month Follow-up (N = 3) | 51 ± 22 |
Collected over From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Blinatumomab 9/28/112 µg/d | — | 9/9 (100%) | 9/9 (100%) |
| Cohort 2: Blinatumomab 112 µg/d | — | 2/2 (100%) | 2/2 (100%) |
| Cohort 3: Blinatumomab 9/28/112 µg/d | — | 12/14 (85.7%) | 14/14 (100%) |
| Cohort 1+3: Blinatumomab 9/28/112µg/d | — | 21/23 (91.3%) | 23/23 (100%) |
| Blinatumomab Overall | — | 23/25 (92%) | 25/25 (100%) |
| Event | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Cohort 1+3: Blinatumomab 9/28/112µg/d | Blinatumomab Overall |
|---|---|---|---|---|---|
| AgranulocytosisBlood and lymphatic system disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| Bone marrow toxicityBlood and lymphatic system disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| NeutropeniaBlood and lymphatic system disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| PyrexiaGeneral disorders | 1/9 | 1/2 | 2/14 | 3/23 | 4/25 |
| PneumoniaInfections and infestations | 3/9 | 1/2 | 2/14 | 5/23 | 6/25 |
| Drug administration errorInjury, poisoning and procedural complications | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| EpilepsyNervous system disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| Neurological symptomNervous system disorders | 1/9 | 1/2 | 0/14 | 1/23 | 2/25 |
| Speech disorderNervous system disorders | 1/9 | 1/2 | 0/14 | 1/23 | 2/25 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| Event | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Cohort 1+3: Blinatumomab 9/28/112µg/d | Blinatumomab Overall |
|---|---|---|---|---|---|
| TremorNervous system disorders | 6/9 | 2/2 | 4/14 | 10/23 | 12/25 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 1/2 | 1/14 | 1/23 | 2/25 |
| ArrhythmiaCardiac disorders | 0/9 | 1/2 | 0/14 | 0/23 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 4/9 | 1/2 | 1/14 | 5/23 | 6/25 |
| FatigueGeneral disorders | 3/9 | 1/2 | 3/14 | 6/23 | 7/25 |
| PyrexiaGeneral disorders | 4/9 | 1/2 | 5/14 | 9/23 | 10/25 |
| Drug hypersensitivityImmune system disorders | 1/9 | 1/2 | 0/14 | 1/23 | 2/25 |
| Fungal infectionInfections and infestations | 1/9 | 1/2 | 0/14 | 1/23 | 2/25 |
| Platelet count decreasedInvestigations | 0/9 | 1/2 | 1/14 | 1/23 | 2/25 |
| White blood cell count decreasedInvestigations | 0/9 | 1/2 | 1/14 | 1/23 | 2/25 |
| Age, Continuous(years) | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Total |
|---|---|---|---|---|
| Mean | 71.7 ± 7.8 | 64.5 ± 13.4 | 57.1 ± 13.6 | 62.9 ± 13.3 |
| Gender(Participants) | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Total |
|---|---|---|---|---|
| Female | 7 | 0 | 4 | 11 |
| Male | 2 | 2 | 10 | 14 |
| Race/Ethnicity, Customized(participants) | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Total |
|---|---|---|---|---|
| White | 9 | 2 | 14 | 25 |
| Relapsed/refractory Status to Last Prior Treatment(participants) | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Total |
|---|---|---|---|---|
| Relapsed | 4 | 1 | 4 | 9 |
| Refractory | 5 | 1 | 10 | 16 |
| Number of Previous Autologous Hematopoietic Stem Cell Transplants (HSCT)(participants) | Cohort 1: Blinatumomab 9/28/112 µg/d | Cohort 2: Blinatumomab 112 µg/d | Cohort 3: Blinatumomab 9/28/112 µg/d | Total |
|---|---|---|---|---|
| None | 7 | 1 | 10 | 18 |
| ≥ 1 | 2 | 1 | 4 | 7 |
The record gives a start of Jul 2012, a primary completion of Jul 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Lymphoma, Large B-Cell, Diffuse →
Amgen Research (Munich) GmbH →